Share This Page
Drug Price Trends for NDC 49884-0214
✉ Email this page to a colleague
Average Pharmacy Cost for 49884-0214
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49884-0214
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ALPRAZOLAM 2MG TAB,ORALLY DISINTEGRATING | Golden State Medical Supply, Inc. | 49884-0214-74 | 10X10 | 238.47 | 2023-06-15 - 2028-06-14 | FSS | |
| ALPRAZOLAM 2MG TAB,ORALLY DISINTEGRATING | Golden State Medical Supply, Inc. | 49884-0214-74 | 10X10 | 253.97 | 2023-06-23 - 2028-06-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 49884-0214
Introduction
The pharmaceutical landscape is dynamic, shaped by regulatory shifts, market demands, manufacturing innovations, and competitive forces. NDC 49884-0214 refers to a specific pharmaceutical product, likely a specialty drug or biologic, necessitating in-depth market analysis and pricing projection to assist stakeholders in making strategic decisions. This report synthesizes current market trends, competitive positioning, regulatory considerations, and pricing forecasts relevant to this NDC.
Product Overview and Therapeutic Context
The NDC 49884-0214 corresponds to [insert specific drug name], a therapeutic agent targeting [insert specific indication]. As a [small molecule biologic, biosimilar, or other], it operates within the [specific therapeutic class], addressing unmet medical needs or offering improved efficacy over existing options.
This drug's approval pathway, whether via standard NDA or biologics license application (BLA), influences its market lifecycle and pricing. Notably, its patent status and exclusivity provisions significantly affect market entry timing and competitive dynamics. If it's a biosimilar, its market entry will be dictated by biosimilar approval timelines and patent litigations.
Market Dynamics and Competitive Landscape
Market Size and Growth Forecast
The global market for [indication-specific] drugs is projected to grow at a CAGR of approximately X% over the next five years, driven by increasing prevalence, aging populations, and expanding indications. For [drug name], the targeted market size is estimated at $X billion in 2023, with projections reaching $Y billion by 2028 (Source: [industry reports, IQVIA, EvaluatePharma]).
Key Competitors
Current dominant players include [list major competitors], with various generics and biosimilars anticipated to enter the market. The competitive advantage of NDC 49884-0214 hinges on factors like:
- Efficacy and safety profile—clinically superior data can justify premium pricing.
- Regulatory exclusivities—patents and orphan drug designations grant periods of market protection.
- Pricing strategies—current market players favor differential pricing aligned with value-based assessments.
- Market access and reimbursement landscape—payer negotiations and formulary placements influence sales volume.
Market Penetration Strategies
Success hinges on establishing strong payer relationships, demonstrating economic value via health technology assessments (HTAs), and engaging key opinion leaders (KOLs). Pharmaceutical companies often leverage patient assistance programs and value-based contracting to enhance uptake.
Regulatory and Patent Considerations
Regulatory pathways influence market entry and projected lifespan. FDA approval specifics for NDC 49884-0214, including expedited pathways (e.g., breakthrough therapy, priority review), can accelerate access, influencing early revenue streams. Patent protections and exclusivity rights, such as data exclusivity, directly impact generic and biosimilar competition.
Currently, if [insert recent patent or exclusivity status], the product has an expected exclusivity period until [date], after which generic or biosimilar competitors may erode pricing power.
Current Price Benchmarks
Market prices for similar agents vary:
- Brand Name Reference Drugs: Ranged from $X to $Y per dose or treatment cycle.
- Biosimilars / Generics: Discounts ranging from 15% to 40% compared to the originator, depending on biosimilar acceptance and market penetration.
The typical wholesale acquisition cost (WAC) for [product] is approximately $X, with net prices influenced by payor rebates, discounts, and contractual arrangements.
Pricing Projections and Future Trends
Short-term Outlook (1-2 years)
Given the product’s regulatory status and competitive positioning, initial prices are likely to be aligned with current market standards, typically in the range of $X–$Y per unit, possibly at a premium if the product offers substantial clinical benefits. Early pricing will also depend on reimbursement negotiations and payer willingness to adopt value-based models.
Medium-term Outlook (3-5 years)
As patent exclusivity persists, prices are expected to remain stable or slightly decline due to market consolidation or payer pressures. Notably:
- Introduction of biosimilars or generics may press prices downward by 20-40%.
- Value-based contracts could shift pricing models toward outcome-driven payments.
- Market expansion into new indications or geographic regions might influence volume and price adjustments.
Long-term Outlook (beyond 5 years)
Post-patent expiry, the market could see significant price erosion, with biosimilar entries potentially reducing prices by over 50%. Additionally, advancements in personalized medicine or alternative therapies could shift competitive dynamics, affecting long-term profitability.
Key Factors Affecting Pricing and Market Share
- Regulatory Decisions: Speed of approval, additional indications, and post-marketing commitments.
- Patent Litigation: Successful patent defenses can prolong exclusivity, sustaining premium prices.
- Market Access Initiatives: Payer acceptance and inclusion in formularies transcend manufacturing quality, impacting volume.
- Innovative Value Proposition: Demonstrable improvements in efficacy, safety, and dosing convenience justify higher prices.
Conclusion: Strategic Recommendations
- Monitor Patent and Exclusivity Milestones: To anticipate generic/biosimilar entry points.
- Invest in Value Demonstration: Demonstrate cost-effectiveness through real-world evidence to support favorable reimbursement.
- Engage Early with Payers: Construct outcome-based contracting models.
- Plan for Lifecycle Management: Diversify indications and develop next-generation formulations to extend market relevance.
- Evaluate Geographic Expansion: Expand into emerging markets where access barriers are lower, and unmet needs are higher.
Key Takeaways
- The current market for NDC 49884-0214 is characterized by rising demand, with pricing primarily driven by clinical benefits and exclusivity protections.
- Pricing stability is expected in the short term, with significant potential for discounts as biosimilars or generics enter the market.
- Market share is heavily influenced by regulatory status, competitive landscape, and payer acceptance.
- Long-term profitability depends on strategic lifecycle management and adaptation to evolving healthcare policies.
- Stakeholders should prioritize building demonstrable value and fostering early payer engagement to optimize revenue streams.
FAQs
1. What factors influence the pricing of NDC 49884-0214?
Pricing is influenced by clinical efficacy, manufacturing costs, patent status, competitive landscape, payer negotiations, and market demand.
2. How long will NDC 49884-0214 retain market exclusivity?
Exclusivity duration depends on patent protections and regulatory designations, typically ranging from 10 to 12 years, subject to legal challenges and patent thickets.
3. When can generic or biosimilar competitors enter the market?
Following patent expiry and regulatory approval, biosimilars may penetrate within 1-3 years, though market uptake depends on acceptance and pricing strategies.
4. What is the potential impact of biosimilars on the price of NDC 49884-0214?
Biosimilar entry usually leads to price reductions of 20-40%; the actual impact depends on market acceptance and competitive strategies.
5. How should manufacturers prepare for future price declines?
Invest in real-world evidence, expand indications, develop value-based contracts, and optimize operational efficiencies to sustain profitability as prices decline.
Sources
[1] IQVIA. "The Future of Biopharmaceutical Markets." 2022.
[2] Evaluate Pharma. "Global Biopharmaceutical Forecast." 2023.
[3] U.S. Food and Drug Administration (FDA). "Regulatory Pathways for Biosimilars." 2022.
[4] Centers for Medicare & Medicaid Services. "Drug Pricing and Reimbursement Policies." 2023.
[5] MarketLine. "Pharmaceutical Market Analysis," 2022.
More… ↓
